Vis enkel innførsel

dc.contributor.authorThaulow, Cecilie Hasselø
dc.contributor.authorHelland, Arne
dc.contributor.authorKongsgaard, Ulf Erik
dc.contributor.authorHøiseth, Gudrun
dc.date.accessioned2024-04-10T06:22:10Z
dc.date.available2024-04-10T06:22:10Z
dc.date.created2023-12-27T08:34:36Z
dc.date.issued2023
dc.identifier.citationTherapeutic Drug Monitoring. 2023, 45 (6), 777-785.en_US
dc.identifier.issn0163-4356
dc.identifier.urihttps://hdl.handle.net/11250/3125619
dc.description.abstractBackground: Interpreting opioid concentrations is challenging because of the lack of reference ranges. Therefore, the authors aimed to propose dose-specific concentration ranges in serum for oxycodone, morphine, and fentanyl in patients with chronic pain, based on concentration measurements from a large number of patients and supported by theoretical pharmacokinetic calculations and previously published concentrations. Methods: The opioid concentrations in patients undergoing therapeutic drug monitoring (TDM) for various indications (TDM group) and patients with cancer (cancer group) were investigated. Patients were divided based on the daily opioid doses, and the 10th and 90th percentiles of the concentrations in each dose interval were evaluated. In addition, the expected average serum concentrations were calculated for each dose interval based on published pharmacokinetic data, and a targeted literature search for previously reported dose-specific concentrations was performed. Results: The opioid concentrations in 1054 patient samples were included: 1004 in the TDM group and 50 in the cancer group. In total, 607 oxycodone, 246 morphine, and 248 fentanyl samples were evaluated. The authors proposed dose-specific concentration ranges based mainly on 10th–90th percentiles of the concentrations measured in patient samples, whereas the calculated average concentrations and previously published concentrations were used to adjust the ranges. In general, results from calculations and concentrations retrieved from previous literature were within the 10th–90th percentiles of concentrations from patient samples. However, the lowest calculated average concentrations of fentanyl and morphine were below the 10th percentiles of patient samples in all dose groups. Conclusions: The proposed dose-specific ranges may be useful for interpreting steady-state opioid serum concentrations in clinical and forensic settings.en_US
dc.language.isoengen_US
dc.publisherLippincott, Williams & Wilkinsen_US
dc.titleOxycodone, Morphine, and Fentanyl in Patients with Chronic Pain: Proposal of Dose-Specific Concentration Rangesen_US
dc.title.alternativeOxycodone, Morphine, and Fentanyl in Patients with Chronic Pain: Proposal of Dose-Specific Concentration Rangesen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holderThis version will not be available due to the publisher's copyright.en_US
dc.source.pagenumber777-785en_US
dc.source.volume45en_US
dc.source.journalTherapeutic Drug Monitoringen_US
dc.source.issue6en_US
dc.identifier.doi10.1097/FTD.0000000000001112
dc.identifier.cristin2217614
cristin.ispublishedtrue
cristin.fulltextpostprint
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel